49ers activate Dre Greenlaw from the PUP listIf you are on the hunt for new ASX dividend shares to buy, then read on. Four that have recently been given buy ratings are listed below. Here's why they could be top options for income investors right now: ( ) Analysts at Bell Potter think that Aspen Group could be an ASX dividend share to buy. It is a leading provider of quality affordable accommodation across residential, land lease, and holiday park communities. The broker currently has a buy rating and $2.75 price target on its shares. As for dividends, it is forecasting dividends per share of 9.5 cents in FY 2025 and then 10.3 cents in FY 2026. Based on the current Aspen share price of $2.47, this will mean of 4% and 4.2%, respectively. ( ) Another ASX dividend share that could be a buy according to Bell Potter is Dexus Convenience Retail REIT. It owns a quality portfolio of Australian service stations and convenience retail assets predominantly located on Australia's eastern seaboard. Bell Potter has a buy rating and $3.30 price target on its shares. In respect to income, the broker expecting the company to pay dividends per share of 20.6 cents in FY 2025 and then 21 cents in FY 2026. Based on its current share price of $2.88 this implies dividend yields of 7.15% and 7.3%, respectively. ( ) A third ASX dividend share that analysts are positive on is National Storage. It is the largest self-storage provider in Australia and New Zealand, with over 250 locations providing tailored storage solutions to in excess of 97,000 residential and commercial customers. Citi is bullish on the company and has a buy rating and $2.70 price target on its shares. As for income, it is forecasting dividends per share of 11.3 cents in FY 2025 and then 11.9 cents in FY 2026. Based on its current share price of $2.36, equates to dividend yields of 4.8% and 5%, respectively, for income investors. ( ) Finally, the team at Goldman Sachs thinks that Telstra could be an ASX dividend share to buy. Its analysts have a buy rating and $4.35 price target on the telco giant's shares. In respect to dividends, Goldman is forecasting fully franked dividends of 19 cents per share in FY 2025 and then 20 cents per share in FY 2026. Based on the current Telstra share price of $4.03, this represents dividend yields of 4.7% and 5%, respectively.
SHENZHEN, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Jayud Global Logistics Limited (NASDAQ: JYD) ("Jayud" or the "Company"), a leading end-to-end supply chain solution provider based in Shenzhen specializing in cross-border logistics, today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least ten consecutive business days; on November 27, 2024, Nasdaq informed the Company it achieved compliance with this Rule. Therefore, Nasdaq considers the prior bid price deficiency matter now closed. About Jayud Global Logistics Limited Jayud Global Logistics Limited is one of the leading Shenzhen-based end-to-end supply chain solution providers in China, focusing on cross-border logistics services. Headquartered in Shenzhen, the Company benefits from the unique geographical advantages of providing a high degree of support for ocean, air, and overland logistics. The Company has established a global operation nexus featuring logistic facilities throughout major transportation hubs in China and globally, with footprints in 12 provinces in Mainland China and 16 countries across six continents. Jayud offers a comprehensive range of cross-border supply chain solution services, including freight forwarding, supply chain management, and other value-added services. With its strong service capabilities and research and development capabilities in proprietary IT systems, the Company provides customized and efficient logistics solutions and develops long-standing customer relationships. For more information, please visit the Company's website: https://ir.jayud.com . Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "may”, "will”, "expect”, "anticipate”, "aim”, "estimate”, "intend”, "plan”, "believe”, "is/are likely to”, "potential”, "continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. For more information, please contact: Jayud Global Logistics Limited Investor Relations Department Email: [email protected] Investor Relations Contact: Matthew Abenante, IRC President Strategic Investor Relations, LLC Tel: 347-947-2093 Email: [email protected]
NoneStockNews.com started coverage on shares of Syros Pharmaceuticals ( NASDAQ:SYRS – Free Report ) in a report released on Thursday. The brokerage issued a sell rating on the stock. Other equities research analysts have also issued research reports about the company. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.33. Check Out Our Latest Stock Analysis on Syros Pharmaceuticals Syros Pharmaceuticals Stock Performance Syros Pharmaceuticals ( NASDAQ:SYRS – Get Free Report ) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the firm posted ($1.35) earnings per share. On average, sell-side analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current year. Insider Transactions at Syros Pharmaceuticals In other news, CEO Conley Chee bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . Also, CFO Jason Haas purchased 45,344 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the acquisition, the chief financial officer now directly owns 124,552 shares in the company, valued at $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here . Insiders purchased a total of 130,707 shares of company stock valued at $206,491 over the last three months. 12.26% of the stock is currently owned by insiders. Institutional Inflows and Outflows Several institutional investors have recently bought and sold shares of SYRS. Opaleye Management Inc. raised its holdings in Syros Pharmaceuticals by 119.1% in the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock valued at $4,213,000 after acquiring an additional 428,175 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Vanguard Group Inc. raised its holdings in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares during the last quarter. Certuity LLC acquired a new position in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Acadian Asset Management LLC raised its holdings in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares during the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds. Syros Pharmaceuticals Company Profile ( Get Free Report ) Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. Read More Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
Dejan Kulusevski rescues draw for Tottenham to deny Rangers
Matt Gaetz says he won't return to Congress next year after withdrawing name for attorney general
( MENAFN - GetNews) "MarketsandMarketsTM"North American Aquafeed market Size, Share, and Growth Trends Report by Ingredient (Soybean, Corn, Fishmeal, Fish Oil, Additives), Species (Fish, Crustaceans, Mollusks), Function (Nutrition, Growth Promoters, Immunity, Texture & Palatability), Lifecycle, Form and Region - Global Industry Forecast to 2029 The North American Aquafeed Market is estimated at USD 1,987.8 million in 2024; it is projected to grow at a CAGR of 6.2% to reach USD 2,687.9 billion by 2029. The markets within North America include the US, Canada, and Mexico. North America is a major importer of aquaculture products. The consumption of fish and seafood remains high in North America. According to the Fisheries of the United States report from 2020, commercial fishers in the US caught 8.4 billion pounds of fisheries worth USD 4.7 billion last year. Additionally, World Bank data shows that aquaculture production in North America reached 645,287 metric tons in 2022. As a result, there is a growing need for specialized aquafeed tailored to different species and life stages to support the growth of the aquafeed market in the region. Aquafeed Market Drivers : Demand for tailor-made aquafeed The demand for tailor-made aquafeed nutrition is gaining importance in the North American region. This has been driven by various factors, such as a rise in a shift towards sustainable aquaculture practices, which has led to a need for customized feed solutions to enhance the nutrition profile of the aquatic species along with reduction of environmental waste. Furthermore, owing to the diverse aquaculture industry in North America, species such as salmon, trout, catfish, and shrimp require specialized nutrition. Thus, tailor-made feed meets the requirements to enhance the nutritional benefits for optimum health solutions. For instance, companies such as ADM (US) focus on formulating customized feed designed to combat a wide variety of aquaculture stressors at any life stage. Aquafeed Market Opportunities : Development of innovative products as a source of protein According to the International Fish Meal and Fish Oil Organization (IFFO), the growing usage of fish meal and fish oil results in increased fishing pressure on wild-feed fish stocks. Thus, there is a growing need to develop alternative ingredients as a source of protein. Also, with the growing consumer preference for food that has minimal impact on the environment, many companies are investing in developing novel products. For instance, BioMar (Denmark) conducted a test to see the effect of insect meal in aquafeed and obtained promising results. Thus, insect meal would have a future as an alternative source of protein in aquaculture feed. The fish segment in the North American aquafeed market is projected to have a dominant share. The North American aquafeed market, particularly for fish, is anticipated to experience significant growth driven by increasing global demand for seafood, advancements in feed technology, and a shift towards more sustainable practices. According to the Food and Agriculture Organization (FAO) of the United Nations, global aquaculture production is projected to reach 114 million tons by 2030, with fish species continuing to dominate production volumes. This growth is largely driven by the rising consumption of fish due to its nutritional benefits and the expansion of aquaculture operations to meet seafood demand. Download PDF Brochure: The US is the dominant region in the North American Aquafeed Market. The US aquafeed market is positioned for growth, driven by a stable increase in aquaculture production. From 2000 to 2022, US production of aquatic animals showed consistent figures, rising from 457,000 tons in 2000 to 478,000 tons in 2022, capturing 9.6% of global regional production. This steady increase highlights the growing demand for aquafeed. Federal support through programs by NOAA and USDA, aimed at enhancing sustainable practices and technological innovation, further stimulates market growth. The continued rise in aquaculture production underscores the increasing need for advanced aquafeed solutions, propelling market expansion. Leading North American aquafeed companies : ADM (US), Cargill, Incorporated (US), dsm-firmenich (Switzerland), Nutreco (Netherlands), Alltech (US), Purina Animal Nutrition (US), Biomar GROUP (Denmark), Kemin Industries (US), Novus International, Inc. (US), Wilbur-Ellis Company LLC (US), Adisseo (France), Aller Aqua Group (Denmark), and Norel Animal Nutrition (Spain), are the key players. ADM (US) Archer Daniels Midland Company (ADM) was founded in 1902 and is headquartered in Chicago. It is an international nutrition and agricultural processing company. ADM has a strong track record in human nutrition, animal nutrition, pet nutrition, and industrial biosolutions. The company manufactures aquafeed products under its Animal Nutrition segment to help farm aquatic species in terms of growth, health, and sustainability. These feeds are formulated to meet the specific dietary requirements of fish and other aquatic animals in aquaculture operations for optimum performance. Procurement, storage, and distribution of agricultural commodities, such as oilseeds, corn, wheat, milo, oats, and barley, as well as their respective derivatives, are done based on this extensive transportation network provided by ADM. It has approximately 160 warehouses and terminals used primarily for bulk storage and 67 innovation centers to further its innovative product offerings. In addition, these processing plants and procurement facilities of ADM further streamline its supply chain skills, some of which are operated by unconsolidated joint ventures. It has a global presence in Europe, Asia Pacific, Africa, South America, and North America through a number of subsidiaries like Golden Peanut Company in the US, ADM do Brazil LTDA in Brazil, Wild Flavors in the US, and ADM Hamburg AG in Germany. Cargill, Incorporated (US) Cargill, Incorporated is engaged in the manufacturing and marketing of food, agricultural, financial, and industrial products and services globally. The diversified business segments include food ingredients and applications, grain origination and oilseed processing, animal nutrition, risk management, and financial services. Within the animal nutrition business, Cargill, Incorporated is one of the major players in the aquafeed market, holding the capacity to deliver a portfolio of feed solutions to meet requirements for most key aquaculture species, including salmon, tilapia, and shrimp. Cargill, Inc. operates business in 70 countries and sells its products in 125 countries. Major subsidiaries like Cargill (Polska) Sp. z oo (Poland), Cargill Siloz (Romania), Cargill Enterprises Inc. (Russia), Cargill Asia Pacific Holdings Pte Limited (Singapore), Cargill RSA (Pty) Limited (South Africa), Cargill España SA (Spain), and Cargill Nordic A/S (Sweden) sustain a huge clientele across the globe. The company is one of the largest suppliers of aquafeed globally and has been working hard on innovation and sustainability to cope with increasing demand from the value chain in aquaculture. Key Questions Addressed by the North American Aquafeed Market Report : What is the current size of the North American aquafeed market? Which are the key players in the market, and how intense is the competition? Which region is projected to account for the largest share of the North American aquafeed market? What kind of information is provided in the company profiles section? What are the factors driving the North American aquafeed market? Schedule a call with our analysts to discuss your business needs: About MarketsandMarkets MarketsandMarketsTM has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. MENAFN16122024003238003268ID1108999874 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.